

## **Reviewer's report**

**Title:** Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

**Version:** 4 **Date:** 11 June 2011

**Reviewer:** Peter Taylor

### **Reviewer's report:**

This interesting study reports the findings of a double blind, placebo-controlled, parallel group study investigating the effects of a mAb with specificity for IL-1 beta in patients with active RA despite methotrexate therapy. The puzzling absence of a dose response deserves further investigation in future studies.

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

### **Declaration of competing interests:**

I declare that I have no competing interests